Satsuma Pharmaceuticals, Inc.

📍 South San Francisco, United States🗓 Founded 2016👥 29 employees💰 Last funded Jan 2017
Pharmaceutical Manufacturing🌐 satsumarx.com
Website LinkedIn
We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidate is STS101 (dihydroergotamine (DHE) nasal powder), which we are focused on developing as an important and differentiated therapeutic option for the acute treatment of migraine
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Japan
1
Frequently asked questions
Who invested in Satsuma Pharmaceuticals, Inc.?
Satsuma Pharmaceuticals, Inc. has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Satsuma Pharmaceuticals, Inc. last raise funding?
The most recent investment in Satsuma Pharmaceuticals, Inc. recorded on gritt.io was in January 2017.
When was Satsuma Pharmaceuticals, Inc. founded?
Satsuma Pharmaceuticals, Inc. was founded in 2016.
What industry is Satsuma Pharmaceuticals, Inc. in?
Satsuma Pharmaceuticals, Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Satsuma Pharmaceuticals, Inc. based?
Satsuma Pharmaceuticals, Inc. is headquartered in South San Francisco, United States.